Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 10/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.83 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvoxamine SCHEMBL35225 | 1.00 | MEN1 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL29014388 | 1.00 | MEN1 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL3863487 | 1.00 | MEN1 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL31022880 | 1.00 | MEN1 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL782847 | 1.00 | MEN1 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL31495839 | 0.93 | MEN1 (0.87) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL27816994 | 0.91 | SLC6A4 (0.95) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL5569574 | 0.91 | SLC6A4 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL341698 | 0.91 | SLC6A4 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL178609 | 0.91 | SLC6A4 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116947691-B | Preparation method of fluvoxamine maleate | 山东锐顺药业有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116947691-A | Preparation method of fluvoxamine maleate | 山东锐顺药业有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-115656370-B | HPLC detection method for fluvoxamine maleate, intermediate and impurities | 湖南省湘中制药有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-113855640-B | Solid pharmaceutical composition for treating mental diseases | 湖南洞庭药业股份有限公司 | 2023-09-26 | — | — | CN | disclosed |
| EP-0659082-B1 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER LAMBERT CO (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5466696-A | Mixtures for treatment of alzheimer's disease | WARNER LAMBERT COMPANY (US) | 1995-11-14 | — | — | US | disclosed |
| US-4085225-A | Oxime ethers having anti-depressive activity | U.S. PHILIPS CORPORATION (US) | 1978-04-18 | — | — | US | disclosed |